AMD treatment is decided based on the AMD subtype, where anti-vascular endothelial growth factor (anti-VEGF) therapy is widely applied for wet-AMD management, whereas no effective treatment is available for dry-AMD, although some treatments have been proposed1,3–5. The gene discussed is VEGFA; the disease is wet macular degeneration.